Cargando…
Phospho-Aspirin-2 (MDC-22) Inhibits Estrogen Receptor Positive Breast Cancer Growth Both In Vitro and In Vivo by a Redox-Dependent Effect
Phospho-aspirin (PA-2) is a novel aspirin derivative that exhibits promising anticancer properties and is considerably safer than conventional aspirin. In this study, we investigated the chemotherapeutic efficacy of PA-2 in preclinical models of estrogen receptor positive (ER+) breast cancer and elu...
Autores principales: | Huang, Liqun, Wong, Chi C., Cheng, Ka W., Rigas, Basil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219766/ https://www.ncbi.nlm.nih.gov/pubmed/25369051 http://dx.doi.org/10.1371/journal.pone.0111720 |
Ejemplares similares
-
Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress
por: Huang, Liqun, et al.
Publicado: (2014) -
Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system
por: Sun, Yu, et al.
Publicado: (2012) -
Targeting Mitochondrial STAT3 with the Novel Phospho-Valproic Acid (MDC-1112) Inhibits Pancreatic Cancer Growth in Mice
por: Mackenzie, Gerardo G., et al.
Publicado: (2013) -
Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics
por: CHENG, KA-WING, et al.
Publicado: (2013) -
Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan
por: Rodriguez Lanzi, Cecilia, et al.
Publicado: (2021)